Chardan Capital Maintains Buy on Immuneering, Maintains $20 Price Target
Benzinga Newsdesk 12 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $20 price target.
Chardan Capital analyst Geulah Livshits maintains Immuneering (NASDAQ:IMRX) with a Buy and maintains $20 price target.